Health Canada Recognized Peptide Therapeutics
Peptide therapeutics are an officially recognized class of prescription medicine in Canada. While many products sold online operate in an unauthorized "research only" grey market, Health Canada has evaluated, safety-tested, and granted formal Drug Identification Numbers (DINs) to several revolutionary peptide chains that have completed rigorous clinical trial programs.
These approved compounds represent the highest standard of pharmaceutical quality — manufactured under strict GMP conditions by companies like Novo Nordisk, Eli Lilly, and Theratechnologies, with full regulatory oversight, batch traceability, and post-market surveillance.
How to Check Your Private Insurance Coverage
Many Canadians with extended workplace health benefits can access these prescription peptide therapies through their private insurance plans. To verify coverage:
- 1Open your workplace health app (Sun Life, Canada Life, Manulife, Blue Cross, or equivalent)
- 2Navigate to "Drug Coverage" or "Formulary Search"
- 3Enter the 8-digit DIN number from the table below (tap the copy button for easy pasting)
- 4The system will confirm whether your plan covers the medication and any applicable co-pay amounts
Health Canada Approved Peptides & DIN Reference
| Generic Name | Brand Name | DIN(s) | Approved Indication | Mechanism |
|---|---|---|---|---|
| Semaglutide | Ozempic® / Wegovy® | Ozempic 1mg pen Wegovy 2.4mg | Type 2 Diabetes Management / Chronic Weight Management | GLP-1 Receptor Agonist |
| Tirzepatide | Mounjaro® / Zepbound® | Mounjaro 5mg Mounjaro 10mg | Type 2 Diabetes Management / Chronic Weight Management | Dual GLP-1/GIP Receptor Agonist |
| Liraglutide | Victoza® / Saxenda® | Saxenda 6mg/mL Victoza 6mg/mL | Type 2 Diabetes Management / Chronic Weight Management | GLP-1 Receptor Agonist |
| Tesamorelin | Egrifta® | Egrifta 1mg | HIV-Associated Abdominal Lipodystrophy (Visceral Fat Reduction) | GHRH Analog / Growth Hormone Stimulator |
| Dulaglutide | Trulicity® | Trulicity 1.5mg | Type 2 Diabetes Management | GLP-1 Receptor Agonist |
| Exenatide | Byetta® / Bydureon® | Bydureon 2mg | Type 2 Diabetes Management | GLP-1 Receptor Agonist (Exendin-4 based) |
| Octreotide | Sandostatin® | Sandostatin LAR 20mg Octreotide injection | Long-acting somatostatin peptide analog for severe cellular growth regulation and gastrointestinal tract stabilization | Somatostatin Analog |
| PT-141 (Bremelanotide) | Vyleesi® | Vyleesi 1.75mg | Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use by Canadian practitioners for neuro-arousal and performance metrics in male research models. | Melanocortin-4 Receptor Agonist |
| Teriparatide | Forteo® | Forteo 250mcg/mL | Human parathyroid hormone analog for bone-tissue regulation and advanced osteoporosis density management | PTH(1-34) Analog / Bone Anabolic Agent |
| Desmopressin | DDAVP® / Stimate® | DDAVP injection | Synthetic vasopressin peptide analog for structural water-retention mapping and endocrine regulation | Vasopressin V2 Receptor Agonist |
| Calcitonin | Miacalcin® | Miacalcin injection | Synthetic peptide hormone for severe hypercalcemia regulation and bone metabolism stabilization | Calcitonin Receptor Agonist / Bone Resorption Inhibitor |
| Gonadorelin | Lutrepulse® (discontinued) / Factrel® | Search AppDiagnostic use | Diagnostic Assessment of Gonadotropic Function | GnRH Analog / LH-FSH Stimulator |
Semaglutide
GLP-1 Receptor AgonistOzempic® / Wegovy®
Type 2 Diabetes Management / Chronic Weight Management
Tirzepatide
Dual GLP-1/GIP Receptor AgonistMounjaro® / Zepbound®
Type 2 Diabetes Management / Chronic Weight Management
Liraglutide
GLP-1 Receptor AgonistVictoza® / Saxenda®
Type 2 Diabetes Management / Chronic Weight Management
Tesamorelin
GHRH Analog / Growth Hormone StimulatorEgrifta®
HIV-Associated Abdominal Lipodystrophy (Visceral Fat Reduction)
Dulaglutide
GLP-1 Receptor AgonistTrulicity®
Type 2 Diabetes Management
Exenatide
GLP-1 Receptor Agonist (Exendin-4 based)Byetta® / Bydureon®
Type 2 Diabetes Management
Octreotide
Somatostatin AnalogSandostatin®
Long-acting somatostatin peptide analog for severe cellular growth regulation and gastrointestinal tract stabilization
PT-141 (Bremelanotide)
Melanocortin-4 Receptor AgonistVyleesi®
Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use by Canadian practitioners for neuro-arousal and performance metrics in male research models.
Teriparatide
PTH(1-34) Analog / Bone Anabolic AgentForteo®
Human parathyroid hormone analog for bone-tissue regulation and advanced osteoporosis density management
Desmopressin
Vasopressin V2 Receptor AgonistDDAVP® / Stimate®
Synthetic vasopressin peptide analog for structural water-retention mapping and endocrine regulation
Calcitonin
Calcitonin Receptor Agonist / Bone Resorption InhibitorMiacalcin®
Synthetic peptide hormone for severe hypercalcemia regulation and bone metabolism stabilization
Gonadorelin
GnRH Analog / LH-FSH StimulatorLutrepulse® (discontinued) / Factrel®
Diagnostic Assessment of Gonadotropic Function
Case Study: Tesamorelin (Egrifta®) & Visceral Fat Reduction
Generic
Tesamorelin
Brand
Egrifta®
DIN
02375230
Mechanism
GHRH Analog
Tesamorelin is a synthetic Growth Hormone-Releasing Hormone (GHRH) analogue explicitly approved by Health Canada for HIV/AIDS patients suffering from lipodystrophy — a metabolic condition causing massive, dangerous accumulations of visceral fat around the abdomen.
The compound works by triggering the pituitary gland to naturally pulse growth hormone in a physiological pattern. This endogenous GH elevation directly targets visceral adipose tissue, reducing dangerous abdominal fat deposits and improving lipid profiles (triglycerides, cholesterol ratios).
Tesamorelin's clinical significance extends beyond its approved indication: it provides direct clinical trial evidence proving the fat-loss mechanics of growth hormone secretagogues under controlled, FDA/Health Canada-reviewed conditions. The mechanism — stimulating natural GH pulsatility to reduce visceral fat — is the same biological pathway targeted by research-grade GHRH analogs like CJC-1295 and Sermorelin, validating the underlying science at the regulatory level.
Clinical Significance
Tesamorelin's Health Canada approval demonstrates that growth hormone secretagogues can meaningfully reduce visceral fat when administered correctly. This regulatory validation provides the strongest possible evidence that the GHRH pathway is a legitimate therapeutic target for body composition improvement — a fact that contextualizes the entire growth hormone secretagogue category within the peptide research community.
The Borderline: Prescription vs. Grey Market Compounds
While the molecules listed above are legally approved as prescription drugs when manufactured by companies like Novo Nordisk, Eli Lilly, or Theratechnologies, buying raw, unlabeled powders online from unverified research vendors bypasses Health Canada's strict laboratory quality controls entirely.
The chemical structure may be identical on paper, but pharmaceutical-grade manufacturing ensures:
Batch Quality Documentation
GMP-certified 99.9%+ purity with batch-specific documentation
Sterility Assurance
Endotoxin-free, particulate-free, validated sterile fill processes
Correct Formulation
Precise pH, osmolality, and excipient profiles for injection safety
Regulatory Oversight
Post-market surveillance, adverse event reporting, recall capability
Harm Reduction Advisory: Researchers using grey-market compounds should always cross-reference batch certificates of analysis against the known molecular structures of these clinically validated peptides. Third-party testing from recognized laboratories (such as Janoshik) provides the closest available verification outside the pharmaceutical supply chain.